Abeona Therapeutics (ABEO) Cash & Current Investments (2010 - 2026)

Abeona Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $168.3 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 99.95% year-over-year to $168.3 million in Q1 2026; TTM through Mar 2026 was $168.3 million, a 99.95% increase from a year earlier, with the FY2025 full-year figure at $191.4 million, up 95.19% from the prior year.
• Cash & Current Investments eased to $168.3 million in Q1 2026 per ABEO's latest filing, from $191.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $225.5 million in Q2 2025 and bottomed at $16.9 million in Q1 2022.
• The 5-year median for Cash & Current Investments is $54.1 million (2023), against an average of $88.6 million.
• Across the five-year window, Cash & Current Investments plunged 80.76% in 2022 and jumped 197.75% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $52.5 million in 2022, then rose by 0.15% to $52.6 million in 2023, then jumped by 86.55% to $98.1 million in 2024, then soared by 95.19% to $191.4 million in 2025, then decreased by 12.09% to $168.3 million in 2026.
• Per Business Quant, the three latest ABEO Cash & Current Investments figures stand at $168.3 million (Q1 2026), $191.4 million (Q4 2025), and $207.5 million (Q3 2025).